Serum is one of the world’s biggest producers of the Covishield vaccine. Serum, Biocon to work on HIV, dengue meds “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics,” said Kiran Mazumdar-Shaw, executive chairperson of Biocon & Biocon Biologics. In return, Biocon’s biologics business arm will get access to 100 million doses of vaccines annually for 15 years, mainly from Serum’s upcoming facility in Pune, with commercialisation rights of the SILS vaccine portfolio (including Covid-19 vaccines) for global markets. That is 25% higher than what Goldman Sachs valued the company at when it invested $150 million last year. BENGALURU: Serum Institute Life Sciences (SILS), a unit of Serum Institute of India, will buy a 15% stake in Biocon Biologics at a post-money valuation of about $5 billion, the two companies said.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |